NKG7 Polyklonaler Antikörper
NKG7 Polyklonal Antikörper für WB, IHC, IP, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, IP, Indirect ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 11532-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
11532-1-PBS bindet in WB, IHC, IP, Indirect ELISA NKG7 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | NKG7 fusion protein Ag2117 |
| Vollständiger Name | natural killer cell group 7 sequence |
| Berechnetes Molekulargewicht | 165 aa, 18 kDa |
| Beobachtetes Molekulargewicht | 18 kDa |
| GenBank-Zugangsnummer | BC015759 |
| Gene symbol | NKG7 |
| Gene ID (NCBI) | 4818 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Natural killer cell granule protein 7 (NKG7) regulates lymphocyte granule exocytosis and downstream inflammation in a broad range of diseases. NKG7 expressed by CD4+ and CD8+ T cells were key in promoting inflammation during visceral leishmaniasis and malaria-two important parasitic diseases. It is expressed by natural killer cells and is critical for controlling cancer initiation, growth, and metastasis (PMID: 32839608; 8458737). In brief, NKG7 is a necessary T-cell intrinsic factor for the cytotoxic function of CD8+ T cells and established NKG7 as a new therapeutic target for cancer immunotherapy (PMID: 34911739).





